U.S. Cell Therapy Manufacturing Market to Reach $6.56 Billion by 2035 as AI and Cancer Demand Drive 14.39% CAGR
Updated
Updated · Precedence Research · Jun 5
U.S. Cell Therapy Manufacturing Market to Reach $6.56 Billion by 2035 as AI and Cancer Demand Drive 14.39% CAGR
1 articles · Updated · Precedence Research · Jun 5
Summary
$6.56 billion is the projected size of the U.S. cell therapy manufacturing market by 2035, up from $1.71 billion in 2025 and $1.97 billion in 2026.
14.39% annual growth is tied to rising clinical development and commercialization of cell therapies, plus demand for scalable, automated production technologies.
2,114,850 new U.S. cancer cases expected in 2026 help explain why oncology was the largest application segment in 2025, while autologous therapies and iPSC-based production also led their categories.
AI and new manufacturing investment are reinforcing that expansion: Nucleus Biologics launched NB-Lux AI in May 2026, while Pennsylvania committed $41.5 million and Johnson & Johnson pledged about $1 billion for new capacity.
With AI managing cell production, what are the unforeseen risks of digitizing and automating human biology?
Will million-dollar cures break the U.S. healthcare system before new payment models can save it?
Can 'off-the-shelf' therapies overcome immune rejection and truly replace personalized treatments?
AI and Investment Propel U.S. Cell Therapy Manufacturing: Overcoming Cost and Access Barriers in 2024
Overview
The U.S. cell therapy manufacturing landscape is rapidly transforming through the integration of artificial intelligence (AI) and advanced manufacturing technologies. These innovations are crucial for enhancing efficiency, improving scalability, and expanding patient access to life-saving treatments. AI, including machine learning and deep learning, is streamlining production and overcoming historical barriers such as high costs and complex processes. As AI's impact grows within cell and gene therapies, the industry is poised for a revolution that will make these advanced treatments more accessible and effective for a wider range of patients.